Friedreich ataxia (FRDA) is an autosomal recessive degenerative disease caused by insufficient expression of frataxin (FXN), a mitochondrial iron-binding protein required for Fe-S cluster assembly. The development of treatments to increase FXN levels in FRDA requires elucidation of the steps involved in the biogenesis of functional FXN. The FXN mRNA is translated to a precursor polypeptide that is transported to the mitochondrial matrix and processed to at least two forms, FXN Friedreich ataxia (FRDA) 2 (OMIM number 229300) is an autosomal recessive disease with an estimated incidence of 1:40,000. Most FRDA patients are apparently healthy at birth and during the first 5-10 years of life; then their gait becomes increasingly unsteady and wide-based and their voluntary movements uncoordinated. Many patients develop hypertrophic cardiomyopathy as well as diabetes, muscle weakness, and skeletal deformities. Although cognitive functions remain largely intact during disease progression, patients develop significant communication difficulties due to dysarthria, which is often compounded by vision and hearing loss. The majority of patients eventually become wheelchair-bound and dependent on others for most daily activities. Cardiac failure is a frequent cause of death at a young age (1).The FRDA locus encodes a mitochondrial protein designated frataxin (FXN), which is expressed at much lower levels in FRDA patients compared with normal individuals (2). In most patients, FXN deficiency results from the presence of an expanded GAA repeat in the first intron of the FRDA gene (2) that causes transcriptional silencing (reviewed in Ref.3). Although FXN is ubiquitously expressed, certain cells (dorsal root ganglia neurons, cardiomyocytes, and pancreatic beta cells) are exquisitely sensitive to frataxin depletion, and the degenerative loss of these particular cells accounts for the major clinical aspects of FRDA (1).Extensive biochemical studies have shown that frataxins across species are conserved iron-binding proteins that can either provide iron for Fe-S cluster assembly and heme synthesis or store iron as a stable mineral (reviewed in Ref. 4). The loss of these properties accounts for impaired iron utilization and increased iron toxicity linked to frataxin deficiency in the mitochondria of such diverse organisms as Saccharomyces cerevisiae, Drosophila, mouse, and humans (5-8). In humans, the mitochondrial alterations caused by FXN deficiency lead to tissue-specific changes in various cellular pathways involved in antioxidant, metabolic, and inflammatory responses, thereby amplifying the pathophysiology of FRDA and promoting disease progression (9 -13).
PAGE 38167:The first sentence of the Abstract should read as follows: During co-translational folding, the nascent polypeptide chain is extruded sequentially from the ribosome exit tunnel and is under severe conformational constraints dictated by the one-dimensional geometry of the tunnel. VOLUME 285 (2010) PAGES 23829 -23841 DOI 10.1074/jbc.A109.092874The prolyl isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer. ), which has been licensed to MitoSciences, Inc. The Mayo Clinic, but not the investigators, has received royalties of less than the federal threshold for significant financial interest.THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 286, NO. 10, p. 8708, March 11, 2011 © 2011 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A. JOURNAL OF BIOLOGICAL CHEMISTRYVOLUME 286 • NUMBER 10 • MARCH 11, 2011 ADDITIONS AND CORRECTIONS This paper is available online at www.jbc.orgWe suggest that subscribers photocopy these corrections and insert the photocopies in the original publication at the location of the original article. Authors are urged to introduce these corrections into any reprints they distribute. Secondary (abstract) services are urged to carry notice of these corrections as prominently as they carried the original abstracts.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.